Alzamend Neuro, Inc. ALZN
1.83
0.01
0.55%
as of 25 Sep
- Market cap
- $8.8M
- P/E
- 0.0×
Follow ALZN
Insider Buys
alert about insiders buying in the last 12 month
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
3.01 | 1.31 | 1.99 | 6.58 |
+8 more quarters Free account |
Net Debt/EBITDA |
2.53 | 0.25 | 1.25 | 4.59 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.38 | 0.97 | 0.79 | 1.17 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.25) | (0.84) | (0.46) | (0.35) | |
Cash per Share |
1.70 | 0.21 | 0.71 | 1.32 | |
Shareholders Equity per Share |
1.30 | 0.22 | 0.57 | 1.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.30 | 0.22 | 0.57 | 1.29 | |
Free Cash Flow |
(1.14) | (2.80) | (1.74) | (1.17) | |
Working Capital |
5.52 | 0.42 | 1.84 | 4.00 | |
Net Current Asset Value |
5.52 | 0.42 | 1.84 | 4.00 | |
| Other line items | |||||
Quick Ratio |
2.77 | 0.53 | 1.46 | 6.20 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.25) | (0.84) | (0.46) | (0.35) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.86 | 0.99 | 1.29 | 0.99 | |
Average Assets |
7.43 | 3.34 | 4.11 | 5.05 | |
Average Common Equity |
5.57 | 2.35 | 2.82 | 4.06 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates